目的探讨两种干预方法缓解早产儿眼底筛查所致疼痛的效果。方法纳入2017年7月~2019年6月某三级甲等专科医院早产儿病房进行眼底筛查的168例早产儿进行研究,依据随机对照原则分为三组,各56例,对照组早产儿采取常规眼底筛查,非营养性吸吮(...目的探讨两种干预方法缓解早产儿眼底筛查所致疼痛的效果。方法纳入2017年7月~2019年6月某三级甲等专科医院早产儿病房进行眼底筛查的168例早产儿进行研究,依据随机对照原则分为三组,各56例,对照组早产儿采取常规眼底筛查,非营养性吸吮(NNS)组早产儿接受NNS护理,25%葡萄糖(GS)+NNS组早产儿接受25%GS安慰奶嘴护理。比较三组早产儿不同时间点疼痛、心率(HR)、血氧饱和度(SpO2)变化情况。结果 NNS组与25%GS+NNS组早产儿筛查过程中、筛查后1 min PIPP评分、HR均低于对照组,SpO2均高于对照组,差异显著(P<0.05);GS+NNS组早产儿筛查过程中、筛查后1 min PIPP评分、HR均低于NNS组,SpO2高于NNS组,差异显著(P<0.05)。结论采取25%GS+NNS的干预方式能够有效减轻早产儿眼底筛查所致疼痛,值得临床推荐。展开更多
Objective:To evaluate whether the efficacy of Getong Tongluo Capsule(葛酮通络胶囊,GTC,consisted of total flavone of Radix Puerariae)on improving patients'quality of life and lowering blood pressure are superior to...Objective:To evaluate whether the efficacy of Getong Tongluo Capsule(葛酮通络胶囊,GTC,consisted of total flavone of Radix Puerariae)on improving patients'quality of life and lowering blood pressure are superior to the extract of Ginkgo biloba(EGB)for patients with convalescent-phase ischemic stroke and primary hypertension.Methods:This randomized,positive-drug-and placebo-controlled,double-blind trial was conducted from September 2015 to October 2017.Totally 477 eligible patients from 18 hospitals in China were randomly assigned in a 2:1:1 ratio to the following interventions,twice a day for 12 weeks:(1)GTC 250 mg plus EGB-matching placebo 40 mg(237 cases,GTC group),(2)EGB 40 mg plus GTC-matching placebo 250 mg(120 cases,EGB group)or(3)GTC-matching placebo 250 mg plus EGB-matching placebo 40 mg(120 cases,placebo group).Moreover,all patients were orally administered aspirin enteric-coated tablets 100 mg,once a day fo r 12 weeks.The primary outcome was the Barthel Index(Bl).The secondary outcomes included the control rate of blood pressure and National Institutes of Health Stroke Scale(NIHSS)scores.The incidence and severity of adverse events(AEs)were calculated and assessed.Results:The Bl relative independence rates,the clinical recovery rates of NIHSS,and the total effective rates of NIHSS in the GTC and EGB groups were significantly higher than the placebo group at 12 weeks after treatment(P<0.05),and no statistical significance was found between the GTC and EGB groups(P>0.05).The control rate of blood pressure in the GTC group was significantly higher than the EGB and placebo groups at 12,18 and 24 weeks after treatment(P<0.01).There were no statistically significant differences in the incidences of AEs,adverse drug reactions,or serious AEs among the 3 groups(P>0.05).Conclusion:GTC exhibited significant efficacy in improving patients'quality of life as well as neurological function and controlling hypertension.展开更多
文摘目的探讨两种干预方法缓解早产儿眼底筛查所致疼痛的效果。方法纳入2017年7月~2019年6月某三级甲等专科医院早产儿病房进行眼底筛查的168例早产儿进行研究,依据随机对照原则分为三组,各56例,对照组早产儿采取常规眼底筛查,非营养性吸吮(NNS)组早产儿接受NNS护理,25%葡萄糖(GS)+NNS组早产儿接受25%GS安慰奶嘴护理。比较三组早产儿不同时间点疼痛、心率(HR)、血氧饱和度(SpO2)变化情况。结果 NNS组与25%GS+NNS组早产儿筛查过程中、筛查后1 min PIPP评分、HR均低于对照组,SpO2均高于对照组,差异显著(P<0.05);GS+NNS组早产儿筛查过程中、筛查后1 min PIPP评分、HR均低于NNS组,SpO2高于NNS组,差异显著(P<0.05)。结论采取25%GS+NNS的干预方式能够有效减轻早产儿眼底筛查所致疼痛,值得临床推荐。
基金Supported by the project of Guangzhou Clinical Medical Research and Transformation Center Pilot Construction(No.20160402003)。
文摘Objective:To evaluate whether the efficacy of Getong Tongluo Capsule(葛酮通络胶囊,GTC,consisted of total flavone of Radix Puerariae)on improving patients'quality of life and lowering blood pressure are superior to the extract of Ginkgo biloba(EGB)for patients with convalescent-phase ischemic stroke and primary hypertension.Methods:This randomized,positive-drug-and placebo-controlled,double-blind trial was conducted from September 2015 to October 2017.Totally 477 eligible patients from 18 hospitals in China were randomly assigned in a 2:1:1 ratio to the following interventions,twice a day for 12 weeks:(1)GTC 250 mg plus EGB-matching placebo 40 mg(237 cases,GTC group),(2)EGB 40 mg plus GTC-matching placebo 250 mg(120 cases,EGB group)or(3)GTC-matching placebo 250 mg plus EGB-matching placebo 40 mg(120 cases,placebo group).Moreover,all patients were orally administered aspirin enteric-coated tablets 100 mg,once a day fo r 12 weeks.The primary outcome was the Barthel Index(Bl).The secondary outcomes included the control rate of blood pressure and National Institutes of Health Stroke Scale(NIHSS)scores.The incidence and severity of adverse events(AEs)were calculated and assessed.Results:The Bl relative independence rates,the clinical recovery rates of NIHSS,and the total effective rates of NIHSS in the GTC and EGB groups were significantly higher than the placebo group at 12 weeks after treatment(P<0.05),and no statistical significance was found between the GTC and EGB groups(P>0.05).The control rate of blood pressure in the GTC group was significantly higher than the EGB and placebo groups at 12,18 and 24 weeks after treatment(P<0.01).There were no statistically significant differences in the incidences of AEs,adverse drug reactions,or serious AEs among the 3 groups(P>0.05).Conclusion:GTC exhibited significant efficacy in improving patients'quality of life as well as neurological function and controlling hypertension.
